Ngs Automation Training Needs Create Barriers In Asia-pacific Labs

By Author: Shreya
Total Articles: 19
Comment this article

Meticulous Research®, a leading global market research company, published a research report titled, 'Asia-Pacific NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Forecast to 2032.'
According to this latest publication from Meticulous Research®, by 2032, the Asia-Pacific NGS automation market could reach about $371 million, growing at a fast 16.3% CAGR from 2025 to 2032. The rise comes from more labs and hospitals using NGS technology for clinical work and research, along with a higher number of cancer cases in the region. Added to that are bigger budgets for pharmaceutical R&D and healthcare overall. Still, the cost of automation workstations makes it harder for many groups to adopt these systems. Even with that challenge, there are clear openings for growth. NGS is being used more often in genetic disease testing, and several governments are backing advanced healthcare technologies. The market does face hurdles, though especially with regulations, ...
... standardization in diagnostic testing, and the need to train staff to handle NGS automation software.
Key Players
The key players operating in the Asia-Pacific NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PrimaDiag SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland).
Asia-Pacific NGS Automation Market: Future Outlook
The Asia-Pacific NGS automation market is segmented by Product (Workstations/Robotic Platforms and Reagents & Consumables), Sequencing Type (Whole Genome Sequencing (WGS), Whole Exome Sequencing, Targeted Genome Sequencing, and Other Sequencing Types), Application (Drug Discovery, Clinical Diagnostics [Reproductive Health Diagnostics, Oncology Diagnostics, Infectious Diseases Diagnostics, and Other Clinical Diagnostics], and Other Applications), End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Other End Users), and Geography. The study also evaluates industry competitors and the market at the country level.
Workstations and Robotic Platforms to Lead Growth in the Asia-Pacific NGS Automation Market
When looking at the Asia-Pacific NGS automation market, one product type stands out. The workstations and robotic platforms segment are likely to grow the fastest over the next few years. Labs are leaning on robotic platforms for liquid handling and pipetting because they speed things up, lower the chance of manual errors, and make workflows smoother. It is not just about efficiency. Rising pharmaceutical R&D spending in the region is also pushing demand for better automation solutions. On top of that, the use of next-generation sequencing (NGS) keeps expanding from cancer research and genetic disease testing to infectious disease studies and drug discovery. With this wider adoption, robotic workstations are becoming more central in both research labs and clinical settings.
Asia-Pacific NGS Automation Market: Whole Genome Sequencing Leads in Market Share
In 2025, whole genome sequencing (WGS) is expected to make up the largest part of the Asia-Pacific NGS automation market. People are using it for a wide range of work from tumor studies and tracking how diseases progress to choosing plants and animals in breeding programs. It is also a go-to method for looking at genetic variations in different populations, which gives a better picture of health patterns. Another big driver is its role in infectious disease research. With WGS, scientists can spot virulence factors and build full resistance profiles of pathogens against antibiotic drugs. That makes it useful in clinical diagnostics, but also in areas like public health, personalized medicine, and disease surveillance.
Clinical Diagnostics Segment to Lead Growth in the Asia-Pacific NGS Automation Market
In the Asia-Pacific NGS automation market, the clinical diagnostics segment is growing the quickest. Hospitals and labs are turning to NGS automation products for NIPT, carrier testing, preimplantation genetic testing, and more. Part of the reason is simple more babies are being born with genetic disorders, and families want answers faster. Awareness of genetic testing is spreading, and new non-invasive prenatal testing (NIPT) products are hitting the market. In China, the CDC found that between 2013 and 2022, there were about 80.77 cases of congenital heart disease per 10,000 births. Numbers like that explain why demand for better testing keeps rising.
Asia-Pacific NGS Automation Market: Pharma and Biotech Firms Hold the Largest Share
In 2025, pharmaceutical and biotechnology companies are expected to take the biggest share of the Asia-Pacific NGS automation market. It makes sense these companies pour huge amounts into R&D, and they are under pressure to find better diagnostics and new therapeutic approaches. The rise of chronic diseases in the region adds to that pressure. To keep up, pharma and biotech labs are leaning more on NGS technologies and automation tools. They need faster results and fewer errors, and that’s exactly what NGS automation delivers.
China Emerges as the Growth Leader in Asia-Pacific NGS Automation Market
In the Asia-Pacific NGS automation market, growth is not spread evenly. Countries like China, Japan, India, South Korea, Australia, Thailand, Singapore, and Indonesia are all included in the analysis, but China clearly stands out. It is expected to post the highest CAGR through 2032. This growth is tied to a few things happening at the same time. The Chinese government has been backing genome sequencing projects and building new healthcare facilities. There is also a huge number of people living with genetic disorders and rare diseases, which increases the demand for NGS automation platforms in diagnostics and research. China is also becoming more active in personalized medicine. Local scientists and pharmaceutical firms are using whole genome sequencing and targeted sequencing to study cancer, infectious diseases, and population genetics. On top of this, R&D investment from pharma and biotech companies is rising, which helps adoption spread faster. Partnerships add another layer of support. A good example is the program run by the Newborn Foundation (U.S.), the Chinese Ministry of Health, and the National Office of Maternal and Child Health Services. For more than ten years, they have worked together on newborn screening for congenital heart defects and neonatal hypoxemia, creating awareness of genetic testing in the country. Other Asia-Pacific markets are also making moves. India is building genomic research hubs and working on low-cost sequencing, while Japan is applying NGS automation in cancer care and regenerative medicine. Together, these efforts show that the Asia-Pacific NGS automation market is evolving quickly, with each country finding its own path to adoption.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5790
Key questions answered in the report:
What are the major drivers fueling the growth of the Asia-Pacific NGS automation market?
Which companies are the leading players in the Asia-Pacific NGS automation market?
Which product type is expected to lead growth in the Asia-Pacific NGS automation market?
Why are robotic platforms and workstations gaining traction in labs and research centers?
Which application segment is growing the fastest in the Asia-Pacific NGS automation market?
Why is the clinical diagnostics segment expected to grow rapidly during the forecast period?
Which country is expected to post the highest CAGR in the Asia-Pacific NGS automation market?
What is the significance of collaborations like the one between the Newborn Foundation and the Chinese Ministry of Health?
How are India and Japan applying NGS automation differently compared to China?
What role does personalized medicine play in expanding NGS automation adoption across Asia-Pacific?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research